Related Experiment Video
Updated: Dec 1, 2025

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics
Margo Dona1, Selma Waaijers2, Susan Richter3
1Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract:
Pheochromocytomas and paragangliomas (PPGLs) caused by mutations in the B-subunit of the succinate dehydrogenase (SDHB) have the highest metastatic rate among PPGLs, and effective systemic therapy is lacking. To unravel underlying pathogenic mechanisms, and to evaluate therapeutic strategies, suitable in vivo models are needed. The available systemic Sdhb knock-out mice cannot model the human PPGL phenotype: heterozygous Sdhb mice lack a disease phenotype, and homozygous Sdhb mice are embryonically lethal. Using CRISPR/cas9 technology, we introduced a protein-truncating germline lesion into the zebrafish sdhb gene. Heterozygous sdhb mutants were viable and displayed no obvious morphological or developmental defects. Homozygous sdhb larvae were viable, but exhibited a decreased lifespan. Morphological analysis revealed incompletely or non-inflated swim bladders in homozygous sdhb mutants at day 6. Although no differences in number and ultrastructure of the mitochondria were observed. Clear defects in energy metabolism and swimming behavior were observed in homozygous sdhb mutant larvae. Functional and metabolomic analyses revealed decreased mitochondrial complex 2 activity and significant succinate accumulation in the homozygous sdhb mutant larvae, mimicking the metabolic effects observed in SDHB-associated PPGLs. This is the first study to present a vertebrate animal model that mimics metabolic effects of SDHB-associated PPGLs. This model will be useful in unraveling pathomechanisms behind SDHB-associated PPGLs. We can now study the metabolic effects of sdhb disruption during different developmental stages and develop screening assays to identify novel therapeutic targets in vivo. Besides oncological syndromes, our model might also be useful for pediatric mitochondrial disease caused by loss of the SDHB gene.
Insights
Researchers developed a zebrafish model for SDHB-deficient pheochromocytomas and paragangliomas (PPGLs). This model mimics key metabolic defects, aiding the study of disease mechanisms and therapeutic strategies for these rare tumors.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Mitochondrial Biology
Background:
- Succinate dehydrogenase B (SDHB) mutations cause pheochromocytomas and paragangliomas (PPGLs) with high metastatic rates.
- Existing mouse models fail to replicate the human SDHB-PPGL phenotype, hindering research.
- Effective systemic therapies for SDHB-PPGLs are currently lacking.
Purpose of the Study:
- To develop a novel in vivo model for studying SDHB-associated PPGLs.
- To investigate the pathogenic mechanisms underlying SDHB-deficient PPGLs.
- To evaluate potential therapeutic strategies for these tumors.
Main Methods:
- CRISPR/cas9 technology was used to introduce a germline mutation into the zebrafish sdhb gene.
- Homozygous sdhb mutant zebrafish larvae were analyzed for morphological, metabolic, and behavioral defects.
- Functional and metabolomic analyses assessed mitochondrial complex 2 activity and succinate levels.
Main Results:
- Homozygous sdhb mutant zebrafish larvae exhibited decreased lifespan and swim bladder defects.
- Metabolic analysis revealed reduced mitochondrial complex 2 activity and significant succinate accumulation.
- These metabolic alterations closely mimic those observed in human SDHB-associated PPGLs.
Conclusions:
- This study presents the first vertebrate animal model that recapitulates the metabolic effects of SDHB-associated PPGLs.
- The zebrafish model provides a valuable tool for unraveling disease mechanisms and identifying therapeutic targets.
- This model may also be applicable to studying pediatric mitochondrial diseases linked to SDHB gene loss.

